Literature DB >> 7963531

CD8+ T lymphocyte-mediated lysis of Chlamydia-infected L cells using an endogenous antigen pathway.

P R Beatty1, R S Stephens.   

Abstract

Intracellular bacterial pathogens have evolved to either grow in the nutrient-rich cytoplasm or remain sequestered within a vacuole. One potentially important selective advantage for growth within a vacuole may be evasion of cell-mediated detection and cytolysis. To address this question we used the endosomally confined bacterium Chlamydia trachomatis, which naturally infects epithelial cells, to examine CTL-mediated lysis of nonphagocytic cells. CTL-mediated lysis of infected target cells was detected, although the increased expression of ICAM-1 by transfection was required. The elimination of CD8+ T cells or addition of brefeldin A or cycloheximide eliminated specific cytolysis, whereas conversely, treatment with chloroquine or ammonium chloride had only minor effects. These results implicate endogenous Ag processing for Chlamydia-specific cytolysis. This work demonstrates CTL-mediated lysis of cells infected with an intracellular bacterium that inhibits lysosomal fusion and is confined to an endosomal vacuole.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7963531

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

Review 1.  Immunity to murine chlamydial genital infection.

Authors:  Richard P Morrison; Harlan D Caldwell
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

2.  T lymphocyte immunity in host defence against Chlamydia trachomatis and its implication for vaccine development.

Authors:  X Yang; R Brunham
Journal:  Can J Infect Dis       Date:  1998-03

3.  Failure to detect HLA-A*6802-restricted CD8+ T cells specific for Chlamydia trachomatis antigens in subjects from trachoma-endemic communities.

Authors:  O S Mahdi; H C Whittle; H Joof; D C Mabey; R L Bailey
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

4.  Acquired immunity to Chlamydia pneumoniae is dependent on gamma interferon in two mouse strains that initially differ in this respect after primary challenge.

Authors:  J M Vuola; V Puurula; M Anttila; P H Mäkelä; N Rautonen
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

5.  The intercellular adhesion molecule type-1 is required for rapid activation of T helper type 1 lymphocytes that control early acute phase of genital chlamydial infection in mice.

Authors:  J U Igietseme; G A Ananaba; J Bolier; S Bowers; T Moore; T Belay; D Lyn; C M Black
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

6.  Cross-reactive cytotoxic T-lymphocyte-mediated lysis of Chlamydia trachomatis- and Chlamydia psittaci-infected cells.

Authors:  P R Beatty; S J Rasmussen; R S Stephens
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

7.  Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin A response.

Authors:  M Johansson; K Schön; M Ward; N Lycke
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

8.  A role for interleukin-6 in host defense against murine Chlamydia trachomatis infection.

Authors:  D M Williams; B G Grubbs; T Darville; K Kelly; R G Rank
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Alteration of HLA-B27 peptide presentation after infection of transfected murine L cells by Shigella flexneri.

Authors:  F Boisgérault; J Mounier; V Tieng; M C Stolzenberg; I Khalil-Daher; M Schmid; P Sansonetti; D Charron; A Toubert
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

10.  Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection.

Authors:  R P Morrison; K Feilzer; D B Tumas
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.